Intralinks Webcast: The Importance of Secure Collaboration in Pharma

Administering clinical trials has many requirements, only one of which is reporting suspected unexpected serious adverse reactions (SUSAR). SUSARs and serious adverse event safety reporting can be challenging in large-scale


18 October 2013

Key-Themes-at-SCRS-Site-Solution-Summit

Administering clinical trials has many requirements, only one of which is reporting suspected unexpected serious adverse reactions (SUSAR). SUSARs and serious adverse event safety reporting can be challenging in large-scale and global trials, yet it is vital for the sponsors of clinical trials. Multiple entities like investigators, health authorities and ethics committees must be alerted of both new SUSARs and previously reported SUSARs in a timely manner. Managing all of this can be perplexing, but using a secure electronic communication method for this process can help.

 

Join us on October 24, 2013 for our Informing the Investigator: Implementing and Automated SUSAR Reporting webcast where Dr. Max Horneck, CEO of maxclincal GmbH Germany, will address these concerns and outline the real-life implementation of a secure collaboration platform for SUSAR reporting in a mid-size pharmaceutical company. We look forward to having Dr. Horneck speak about this topic and hope to see you there!

To register for our Informing the Investigator: Implementing and Automated SUSAR Reporting webcast, please click here.



Britany DiCicco

Britany DiCicco

Britany DiCicco supports the enterprise product marketing team at Intralinks focusing on market analysis, positioning, messaging and go-to-market initiatives. Britany’s previous experience at Intralinks included analyst relations, competitive intelligence, and marketing. She graduated from Northeastern University with a degree in Economics.